Apr. 18 at 12:41 AM
PickAlpha Evening Insights | 2026-04-17 - Trade Ideas For The Next Trading Day
1/2 Long
$ENTA — Intraday (0–1d) • Other
Plan: If ESCMID oral reiterates >=7 days symptom-resolution improvement, long
$ENTA at next regular-session open; hold next 1–3 sessions.
Enanta’s Apr. 18 ESCMID oral session on zelicapavir in high-risk adults with RSV is slated to provide Phase 2b RSVHR detail previously described as about a one-week improvement in complete symptom resolution, lower hospitalization rate, and new exposure-multiple analyses over EC90. A reiterated ~one-week benefit is an easy headline for differentiation and later-stage/partnering value, making this a near-term catalyst for ENTA sentiment.
Risk: Exit if symptom-resolution improvement is under 7 days. • Valid until 2026-04-24 20:37 ET
Trade credibility: actionability ★★★☆☆ | timeliness ★★★☆☆ | clarity ★★★★☆
